[go: up one dir, main page]

CR20210202A - Compuestos, composiciones y métodos para modular la actividad cdk9 - Google Patents

Compuestos, composiciones y métodos para modular la actividad cdk9

Info

Publication number
CR20210202A
CR20210202A CR20210202A CR20210202A CR20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A CR 20210202 A CR20210202 A CR 20210202A
Authority
CR
Costa Rica
Prior art keywords
modulating
compositions
compounds
methods
cdk9 activity
Prior art date
Application number
CR20210202A
Other languages
English (en)
Inventor
Joseph VACCA
David Freeman
Andrew Tasker
Peter Mikochik
Original Assignee
Kronos Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc
Publication of CR20210202A publication Critical patent/CR20210202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Inhibidores de CDK9 que son derivados de pirazol[1,5-α]pirimidina y sales de los mismos, correspondientes a la fórmula (I): (I).
CR20210202A 2018-10-30 2019-10-29 Compuestos, composiciones y métodos para modular la actividad cdk9 CR20210202A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752635P 2018-10-30 2018-10-30
US201962884993P 2019-08-09 2019-08-09
US201962910058P 2019-10-03 2019-10-03
PCT/US2019/058482 WO2020092314A1 (en) 2018-10-30 2019-10-29 Compounds, compositions, and methods for modulating cdk9 activity

Publications (1)

Publication Number Publication Date
CR20210202A true CR20210202A (es) 2022-02-08

Family

ID=70328627

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210202A CR20210202A (es) 2018-10-30 2019-10-29 Compuestos, composiciones y métodos para modular la actividad cdk9

Country Status (20)

Country Link
US (3) US11155560B2 (es)
EP (1) EP3873911A4 (es)
JP (1) JP7385658B2 (es)
KR (1) KR20210068597A (es)
CN (1) CN112996790B (es)
AU (1) AU2019370200B2 (es)
BR (1) BR112021008176A2 (es)
CA (1) CA3118472A1 (es)
CO (1) CO2021005502A2 (es)
CR (1) CR20210202A (es)
DO (1) DOP2021000066A (es)
IL (1) IL282254A (es)
MA (1) MA54092A (es)
MD (1) MD20210033A2 (es)
MX (1) MX2021004769A (es)
PE (1) PE20212196A1 (es)
PH (1) PH12021550857A1 (es)
SG (1) SG11202104229WA (es)
WO (1) WO2020092314A1 (es)
ZA (1) ZA202102609B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092314A1 (en) * 2018-10-30 2020-05-07 Kronos Bio, Inc. Compounds, compositions, and methods for modulating cdk9 activity
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
WO2022098843A1 (en) * 2020-11-05 2022-05-12 Kronos Bio, Inc. Compounds and methods for modulating cdk9 activity
CN116761609A (zh) * 2021-01-22 2023-09-15 上海海雁医药科技有限公司 取代的吡唑并[1,5-a]嘧啶-7-胺衍生物、其组合物及医药上的用途
EP4436569A1 (en) * 2021-11-24 2024-10-02 Kronos Bio, Inc. Polymorphic and salt forms of (ls,3s)-n-(5-(pentan-3- yl)pyrazolo[l,5-a]pyrimidin-7-yl)cyclopentane-l,3-diamine
AU2023312111A1 (en) * 2022-07-22 2025-02-06 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt and polymorph of substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative and use thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389632A (en) 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
AU680370B2 (en) 1994-06-21 1997-07-24 Otsuka Pharmaceutical Factory, Inc. Pyrazolo(1,5-a)pyrimidine derivative
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
KR20020047198A (ko) 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
JP2002308879A (ja) 2001-04-13 2002-10-23 Nippon Soda Co Ltd ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
EP1504004B1 (en) 2002-05-10 2007-06-27 SmithKline Beecham Corporation Substituted pyrazolopyrimidines
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
BRPI0314001B8 (pt) * 2002-09-04 2021-05-25 Merck Sharp & Dohme pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
KR20050033659A (ko) 2002-09-04 2005-04-12 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로[1,5-ａ]피리미딘 화합물
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
GB0305559D0 (en) 2003-03-11 2003-04-16 Teijin Ltd Compounds
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
EP1697369A1 (en) 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US8018479B2 (en) 2008-08-27 2011-09-13 Lexmark International, Inc. Method and system for correcting the linearity error in electrophotographic devices
CN101039945A (zh) * 2004-08-13 2007-09-19 帝人制药株式会社 吡唑并[1,5－a]嘧啶衍生物
JP2008524330A (ja) 2004-12-21 2008-07-10 シェーリング コーポレイション ピラゾロ［１，５−Ａ］ピリミジンアデノシンＡ２ａ受容体アンタゴニスト
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
US7645762B2 (en) 2005-10-06 2010-01-12 Schering Corporation Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
BRPI0712016A2 (pt) 2006-05-22 2011-12-27 Schering Corp pirazolo[1,5-a]pirimidinas
AU2008261027A1 (en) 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
US20100317607A1 (en) 2007-06-27 2010-12-16 Infectious Disease Research Institute Use of compounds for preparing anti-tuberculosis agents
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
KR101851130B1 (ko) 2009-12-04 2018-04-23 센화 바이오사이언시즈 인코포레이티드 Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
CN102770435B (zh) 2010-02-26 2015-11-25 田边三菱制药株式会社 吡唑并嘧啶类化合物及其作为pde10抑制剂的用途
AU2011221849B2 (en) 2010-03-05 2015-04-02 Kyowa Kirin Co., Ltd. Pyrazolopyrimidine derivative
KR101970837B1 (ko) 2010-06-24 2019-04-19 길리애드 사이언시즈, 인코포레이티드 항바이러스제로서의 피라졸로[1,5-ａ]피리미딘
KR101995013B1 (ko) 2010-07-13 2019-07-02 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8957077B2 (en) 2010-09-30 2015-02-17 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE 10 inhibitors
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
CN104066736B (zh) 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
ES2739150T3 (es) 2012-02-17 2020-01-29 Millennium Pharm Inc Inhibidores de pirazolopirimidinilo de la enzima activadora de ubiquitina
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
EP2920181B1 (en) 2012-11-16 2019-01-09 University Health Network Pyrazolopyrimidine compounds
JP6534650B2 (ja) 2013-03-14 2019-06-26 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素の阻害剤
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
AU2015240518A1 (en) 2014-04-05 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107530329B (zh) 2015-03-09 2021-10-08 奥瑞基尼探索技术有限公司 用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US9828381B2 (en) 2015-04-20 2017-11-28 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR102707968B1 (ko) 2015-10-01 2024-09-20 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
JP2018199623A (ja) 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
WO2017180499A2 (en) 2016-04-13 2017-10-19 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
CN117946114A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
WO2019023654A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology DISCOVERING SMALL MOLECULES TARGETING THE ANDROGEN RECEPTOR AND USES THEREOF
WO2020092314A1 (en) * 2018-10-30 2020-05-07 Kronos Bio, Inc. Compounds, compositions, and methods for modulating cdk9 activity

Also Published As

Publication number Publication date
MA54092A (fr) 2021-09-08
EP3873911A4 (en) 2022-06-22
US20220002305A1 (en) 2022-01-06
CO2021005502A2 (es) 2021-09-20
DOP2021000066A (es) 2021-10-31
MD20210033A2 (ro) 2021-10-31
ZA202102609B (en) 2023-02-22
US20200131189A1 (en) 2020-04-30
CN112996790A (zh) 2021-06-18
BR112021008176A2 (pt) 2021-08-03
JP2022505268A (ja) 2022-01-14
US20240132506A1 (en) 2024-04-25
IL282254A (en) 2021-05-31
PE20212196A1 (es) 2021-11-16
US11155560B2 (en) 2021-10-26
WO2020092314A1 (en) 2020-05-07
AU2019370200A1 (en) 2021-06-10
EP3873911A1 (en) 2021-09-08
PH12021550857A1 (en) 2021-12-06
SG11202104229WA (en) 2021-05-28
KR20210068597A (ko) 2021-06-09
AU2019370200B2 (en) 2024-12-19
MX2021004769A (es) 2021-08-24
CA3118472A1 (en) 2020-05-07
US11845754B2 (en) 2023-12-19
CN112996790B (zh) 2023-11-03
JP7385658B2 (ja) 2023-11-22

Similar Documents

Publication Publication Date Title
CR20210202A (es) Compuestos, composiciones y métodos para modular la actividad cdk9
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MX2023001876A (es) Derivados de rapamicina.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201690752A1 (ru) Ингибиторы g12c kras
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
EA201991884A2 (ru) Ингибиторы g12c kras
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ726055A (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016016517A (es) Inhibidores de fosfatidilinositol 3-cinasa.
NZ629037A (en) Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
GEP20247655B (en) Crystalline salt forms of kinase inhibitor
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12022550497A1 (en) Perk inhibiting compounds
MX2020013757A (es) Inhibidor del fgfr, metodo de preparacion y aplicacion del mismo.
EA201990046A1 (ru) Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета